<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38977844</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2730-664X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Communications medicine</Title><ISOAbbreviation>Commun Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Complex patterns of multimorbidity associated with severe COVID-19 and long COVID.</ArticleTitle><Pagination><StartPage>94</StartPage><MedlinePgn>94</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">94</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s43856-024-00506-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early evidence that patients with (multiple) pre-existing diseases are at highest risk for severe COVID-19 has been instrumental in the pandemic to allocate critical care resources and later vaccination schemes. However, systematic studies exploring the breadth of medical diagnoses are scarce but may help to understand severe COVID-19 among patients at supposedly low risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically harmonized &gt;12 million primary care and hospitalisation health records from ~500,000 UK Biobank participants into 1448 collated disease terms to systematically identify diseases predisposing to severe COVID-19 (requiring hospitalisation or death) and its post-acute sequalae, Long COVID.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Here we identify 679 diseases associated with an increased risk for severe COVID-19 (n&#x2009;=&#x2009;672) and/or Long COVID (n&#x2009;=&#x2009;72) that span almost all clinical specialties and are strongly enriched in clusters of cardio-respiratory and endocrine-renal diseases. For 57 diseases, we establish consistent evidence to predispose to severe COVID-19 based on survival and genetic susceptibility analyses. This includes a possible role of symptoms of malaise and fatigue as a so far largely overlooked risk factor for severe COVID-19. We finally observe partially opposing risk estimates at known risk loci for severe COVID-19 for etiologically related diseases, such as post-inflammatory pulmonary fibrosis or rheumatoid arthritis, possibly indicating a segregation of disease mechanisms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results provide a unique reference that demonstrates how 1) complex co-occurrence of multiple - including non-fatal - conditions predispose to increased COVID-19 severity and 2) how incorporating the whole breadth of medical diagnosis can guide the interpretation of genetic risk loci.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pietzner</LastName><ForeName>Maik</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3437-9963</Identifier><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany. maik.pietzner@bih-charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Healthcare University Research Institute, Queen Mary University of London, London, UK. maik.pietzner@bih-charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. maik.pietzner@bih-charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denaxas</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Heart Foundation Data Science Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasmeen</LastName><ForeName>Summaira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-9326-7227</Identifier><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Zentrum M&#xfc;nchen - German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9510-5646</Identifier><AffiliationInfo><Affiliation>Precision Healthcare University Research Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4666-0923</Identifier><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Zentrum M&#xfc;nchen - German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastenm&#xfc;ller</LastName><ForeName>Gabi</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2368-7322</Identifier><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Zentrum M&#xfc;nchen - German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hemingway</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2279-0624</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK. h.hemingway@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK. h.hemingway@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK. h.hemingway@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Langenberg</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5017-7344</Identifier><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany. claudia.langenberg@qmul.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Healthcare University Research Institute, Queen Mary University of London, London, UK. claudia.langenberg@qmul.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. claudia.langenberg@qmul.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG074879</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG069901</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063744</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059093</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG081322</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Commun Med (Lond)</MedlineTA><NlmUniqueID>9918250414506676</NlmUniqueID><ISSNLinking>2730-664X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Jul 01:2023.05.23.23290408. doi: 10.1101/2023.05.23.23290408</RefSource><PMID Version="1">39006431</PMID></CommentsCorrections></CommentsCorrectionsList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Early in the COVID-19 pandemic it was clear that people with multiple chronic diseases were vulnerable and needed special protection, such as shielding. However, many people without such diseases required hospital care or died from COVID-19. Here, we investigated the importance of underlying diseases, including mild diseases not requiring hospitalization, for COVID-19 outcomes. Using information from electronic health records we find that many severe, but also less severe diseases increase the risk for severe COVID-19 and its impact on health even months after acute infection (Long COVID). This included an almost two-fold higher risk among people that reported poor well-being and fatigue. Our findings show the value of using primary care health records and the need to consider all the medical history of patients to identify those in need of special protection.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></OtherAbstract><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>8</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38977844</ArticleId><ArticleId IdType="pmc">PMC11231221</ArticleId><ArticleId IdType="doi">10.1038/s43856-024-00506-x</ArticleId><ArticleId IdType="pii">10.1038/s43856-024-00506-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinically extremely vulnerable receive updated guidance in line with new national restrictions. GOV.UK https://www.gov.uk/government/news/clinically-extremely-vulnerable-receive-updated-guidance-in-line-with-new-national-restrictions (2024).</Citation></Reference><Reference><Citation>Kompaniyets L, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. Prev. Chronic Dis. 2021;18:E66. doi: 10.5888/pcd18.210123.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd18.210123</ArticleId><ArticleId IdType="pmc">PMC8269743</ArticleId><ArticleId IdType="pubmed">34197283</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PloS One. 2021;16:e0247461. doi: 10.1371/journal.pone.0247461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeigue PM, et al. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Med. 2020;17:1&#x2013;17. doi: 10.1371/journal.pmed.1003374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003374</ArticleId><ArticleId IdType="pmc">PMC7575101</ArticleId><ArticleId IdType="pubmed">33079969</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature. 2023;617:764&#x2013;768. doi: 10.1038/s41586-023-06034-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06034-3</ArticleId><ArticleId IdType="pmc">PMC10208981</ArticleId><ArticleId IdType="pubmed">37198478</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. Nature621, E7&#x2013;E26 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482689</ArticleId><ArticleId IdType="pubmed">37674002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W-Q, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS One. 2017;12:e0175508. doi: 10.1371/journal.pone.0175508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0175508</ArticleId><ArticleId IdType="pmc">PMC5501393</ArticleId><ArticleId IdType="pubmed">28686612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203&#x2013;209. doi: 10.1038/s41586-018-0579-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0579-z</ArticleId><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen JH, et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Lancet Digit. Health. 2022;4:e542&#x2013;e557. doi: 10.1016/S2589-7500(22)00091-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00091-7</ArticleId><ArticleId IdType="pmc">PMC9179175</ArticleId><ArticleId IdType="pubmed">35690576</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammi, V. et al. Genome-wide Association Study of Long COVID Authors. 1&#x2013;25 (2023).</Citation></Reference><Reference><Citation>Wu P, et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. JMIR Med. Inform. 2019;7:e14325. doi: 10.2196/14325.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14325</ArticleId><ArticleId IdType="pmc">PMC6911227</ArticleId><ArticleId IdType="pubmed">31553307</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas S. Mapping the Read2/CTV3 controlled clinical terminologies to Phecodes in UK Biobank primary care electronic health records: implementation and evaluation. Proc Am. Med. Inform. Assoc. Annu. Symp. 2021;2021:362&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861677</ArticleId><ArticleId IdType="pubmed">35308936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastarache L. Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS. Annu. Rev. Biomed. Data Sci. 2021;4:1&#x2013;19. doi: 10.1146/annurev-biodatasci-122320-112352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biodatasci-122320-112352</ArticleId><ArticleId IdType="pmc">PMC9307256</ArticleId><ArticleId IdType="pubmed">34465180</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C, et al. Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat. Commun. 2023;14:1948. doi: 10.1038/s41467-023-37653-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37653-z</ArticleId><ArticleId IdType="pmc">PMC10080528</ArticleId><ArticleId IdType="pubmed">37029117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan V, et al. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. Lancet Digit. Health. 2023;5:e16&#x2013;e27. doi: 10.1016/S2589-7500(22)00187-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00187-X</ArticleId><ArticleId IdType="pubmed">36460578</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabasi A, Albert R. Emergence of scaling in random networks. Science. 1999;286:509&#x2013;512. doi: 10.1126/science.286.5439.509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5439.509</ArticleId><ArticleId IdType="pubmed">10521342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbatchou J, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 2021;53:1097&#x2013;1103. doi: 10.1038/s41588-021-00870-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00870-7</ArticleId><ArticleId IdType="pubmed">34017140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 2015;47:291&#x2013;295. doi: 10.1038/ng.3211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3211</ArticleId><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 2018;50:693&#x2013;698. doi: 10.1038/s41588-018-0099-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0099-7</ArticleId><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472&#x2013;477. doi: 10.1038/s41586-021-03767-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03767-x</ArticleId><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int. J. Epidemiol. 2017;46:1734&#x2013;1739. doi: 10.1093/ije/dyx034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyx034</ArticleId><ArticleId IdType="pmc">PMC5510723</ArticleId><ArticleId IdType="pubmed">28398548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7:e34408. doi: 10.7554/eLife.34408.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.34408</ArticleId><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383. doi: 10.1371/journal.pgen.1004383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004383</ArticleId><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet. 2021;17:e1009440. doi: 10.1371/journal.pgen.1009440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1009440</ArticleId><ArticleId IdType="pmc">PMC8504726</ArticleId><ArticleId IdType="pubmed">34587156</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S, et al. Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update. Mol. Psychiatry. 2023;28:4056&#x2013;4069. doi: 10.1038/s41380-023-02171-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02171-3</ArticleId><ArticleId IdType="pubmed">37491461</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92&#x2013;98. doi: 10.1038/s41586-020-03065-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03065-y</ArticleId><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Letter TM. An EUA for baricitinib (Olumiant) for COVID-19. Med. Lett. Drugs Ther. 2020;62:202&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">33451175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 2021;384:795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang TN, et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell. 2021;184:460&#x2013;475.e21. doi: 10.1016/j.cell.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7654323</ArticleId><ArticleId IdType="pubmed">33278358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimalakonda A, et al. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol. Ther. 2021;11:1763&#x2013;1776. doi: 10.1007/s13555-021-00596-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13555-021-00596-8</ArticleId><ArticleId IdType="pmc">PMC8484413</ArticleId><ArticleId IdType="pubmed">34471993</ArticleId></ArticleIdList></Reference><Reference><Citation>Elyoussfi S, Rane SS, Eyre S, Warren RB. TYK2 as a novel therapeutic target in psoriasis. Expert Rev. Clin. Pharmacol. 2023;16:549&#x2013;558. doi: 10.1080/17512433.2023.2219054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2023.2219054</ArticleId><ArticleId IdType="pubmed">37287330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strobl B, et al. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J. Immunol. Baltim. Md. 2005;175:4000&#x2013;4008.</Citation><ArticleIdList><ArticleId IdType="pubmed">16148148</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, et al. A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program. PLoS Genet. 2022;18:e1010113. doi: 10.1371/journal.pgen.1010113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1010113</ArticleId><ArticleId IdType="pmc">PMC9049369</ArticleId><ArticleId IdType="pubmed">35482673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadista J, et al. Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. EBioMedicine. 2021;65:103277. doi: 10.1016/j.ebiom.2021.103277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103277</ArticleId><ArticleId IdType="pmc">PMC7946355</ArticleId><ArticleId IdType="pubmed">33714028</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, et al. A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. Am. J. Respir. Crit. Care Med. 2022;206:1220&#x2013;1229. doi: 10.1164/rccm.202109-2166OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202109-2166OC</ArticleId><ArticleId IdType="pmc">PMC9746845</ArticleId><ArticleId IdType="pubmed">35771531</ArticleId></ArticleIdList></Reference><Reference><Citation>pietznerm. comp-med/phecode-covid19-ukb: v1.0. [object Object] 10.5281/ZENODO.10984028 (2024).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>